LEADER 05451nam 2200985 450 001 9910466241703321 005 20200520144314.0 010 $a1-63157-547-3 035 $a(CKB)3710000000769107 035 $a(BEP)4612326 035 $a(OCoLC)955878591 035 $a(CaBNVSL)swl00406775 035 $a(MiAaPQ)EBC4612326 035 $a(Au-PeEL)EBL4612326 035 $a(CaPaEBR)ebr11238975 035 $a(CaONFJC)MIL942080 035 $a(OCoLC)956646278 035 $a(EXLCZ)993710000000769107 100 $a20160805d2016 fy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aHealth financing without deficits $ereform that sidesteps political gridlock /$fPhilip J. Romero and Randy S. Miller 205 $aFirst edition. 210 1$aNew York, New York (222 East 46th Street, New York, NY 10017) :$cBusiness Expert Press,$d2016. 215 $a1 online resource (xiii, 123 pages) 225 1 $aEconomics collection,$x2163-7628 311 $a1-63157-546-5 320 $aIncludes bibliographical references (pages 117-118) and index. 327 $aPart I. The economy's vampire: health care -- 1. Health care, deficits, and the economy -- 2. The absent free market -- 3. The economy's vampire -- Part II. Three generations of reform proposals -- 4. The new deal and its progenitors -- 5. World War II, tax deductibility, and the Fair Deal -- 6. Medicare and Medicaid -- 7. Hillarycare and its progeny -- Part III. What is wrong with Democratic and Republican plans -- 8. 2016 plans -- Part IV. The key problems in American health policy -- 9. Problem I, unlimited demand due to third party payment -- 10. Problem II, high costs = poor access -- 11. Problem III, the health cartel -- 12. Obamacare -- 13. The shadow of 2018 -- Part V. A nonpartisan health financing alternative: HIRB -- 14. Bending the curve on funding health-care cost -- 15. Financing basics -- 16. HIRB and public policy -- 17. Why HIRB works -- 18. HIRB's robustness over a range of interest rates -- 19. A health insurance requisite -- 20. Summation -- 21. HIRB's versatility -- Part VI. Conclusion -- 22. What Democrats get wrong about health reform -- 23. What Republicans get wrong about health reform -- 24. The path to a sustainable health system -- Glossary -- Notes -- Bibliography -- For more about HIRB -- Index. 330 3 $aAmerica's health system has been a polarizing issue in most presidential campaigns in our lifetimes. It is hardly surprising that an industry that consumes nearly one in every five dollars spent in the U.S. economy has loomed over our politics. Its only competition in the last few decades was the nuclear standoff with the Soviet Union during the Cold War. It will be prominent again in 2016 and beyond. This book will guide you through the fusillade of charges, and promises, you will hear in political campaigns about health care and "reform." They will occur now that the fiscal calamity of Boomer retirement is no longer a threat: it is here. For all the attention Social Security receives, Medicare is the truly scary entitlement program, with unfunded liabilities many times larger. This book also offers a powerful tool of reform. The Health Insurance Revenue Bond (HIRB) is a new and completely self-liquidating financing approach that fully funds escalating liabilities such as health care-- without deficits. If you can't bend the curve on health costs, bend the curve on the cost of funding. The HIRB program can assist governments in developed nations to begin the long and painful process of deleveraging. 410 0$aEconomics collection.$x2163-7628 606 $aHealth care reform$xEconomic aspects$zUnited States 606 $aMedical policy$xEconomic aspects$zUnited States 606 $aMedical care, Cost of$zUnited States 606 $aHealth Care Reform$xeconomics$zUnited States 606 $aHealth Policy$xeconomics$zUnited States 606 $aHealth Care Costs$zUnited States 608 $aElectronic books. 610 $a2016 campaign 610 $aACA 610 $aAffordable Care Act 610 $abending the cost curve 610 $abond 610 $adeficit 610 $adeleveraging 610 $afinancing 610 $ahealth care 610 $ahealth finance 610 $ahealth policy 610 $ahealth reform 610 $ahealth security 610 $aHIRB 610 $ainflation 610 $aliabilities 610 $aMedicaid 610 $amedical inflation 610 $aMedicare 610 $amunicipal bond 610 $aOPEBs 610 $aother post employment benefits 610 $apensions 610 $apolitics 610 $apost retirement benefits 610 $apresidential campaign 610 $arevenue bond 610 $astates 615 0$aHealth care reform$xEconomic aspects 615 0$aMedical policy$xEconomic aspects 615 0$aMedical care, Cost of 615 2$aHealth Care Reform$xeconomics 615 2$aHealth Policy$xeconomics 615 2$aHealth Care Costs 676 $a362.10973 700 $aRomero$b Philip J.$0865299 702 $aMiller$b Randy S. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910466241703321 996 $aHealth financing without deficits$92267882 997 $aUNINA LEADER 06577nam 22006015 450 001 9910254533503321 005 20230829003214.0 010 $a3-319-34214-2 024 7 $a10.1007/978-3-319-34214-6 035 $a(CKB)3710000000837844 035 $a(EBL)4659329 035 $a(DE-He213)978-3-319-34214-6 035 $a(MiAaPQ)EBC4659329 035 $a(PPN)194804992 035 $a(EXLCZ)993710000000837844 100 $a20160826d2016 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHepatocellular Carcinoma $eDiagnosis and Treatment /$fedited by Brian I. Carr 205 $a3rd ed. 2016. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2016. 215 $a1 online resource (594 p.) 225 1 $aCurrent Clinical Oncology,$x2364-1134 300 $aIncludes index. 311 $a3-319-34212-6 327 $aPart A. Causes, Biological and Molecular bases of HCC -- Chapter 1. Epidemiology of Hepatocellular Carcinoma -- Chapter 2. Environmental Carcinogens and Risk for Human Liver Cancer -- Chapter 3. Molecular Mechanisms of Hepatocellular Carcinoma -- Chapter 4. Chemically-Induced Hepatocarcinogenesis -- Chapter 5. Molecular Profiling of Human Hepatocellular Carcinoma -- Chapter 6. Genomic signatures of risk factors and molecular identification of HCC subtypes -- Chapter 7. MicroRNAs and hepatocellular carcinoma -- Chapter 8. Non-tumor prognostic factors in hepatocellular carcinoma -- Chapter 9. Gut microbiota and HCC -- Chapter 10. Hepatocellular Carcinoma as a Paradigm for a Systemic Evolutionary Approach to Cancer -- Chapter 11. HCC and its Microenvironment -- Chapter 12. Circulating tumor cells (Liquid Tumor Biopsy) in hepatocellular carcinoma: biology, methodologies, and clinical implications -- Chapter 13. Role of the immune system in hepatocellular carcinoma: Implications for existing and novel therapies -- Chapter 14. Inter- and Intratumor Heterogeneity in Hepatocellular Carcinoma -- Chapter 15. Systemic inflammation: a new prognostic domain and source of therapeutic targets in hepatocellular carcinoma -- Chapter 16. Hepatocellular Carcinoma Associated with Hepatitis B virus -- Chapter 17. Hepatitis C and Hepatocellular Carcinoma -- Chapter 18. Obesity, NASH and HCC -- Chapter 19. Metabolic Disease and Hepatocellular Carcinoma -- Part B. Diagnosis -- Chapter 20. Pathologic Aspects of Hepatocellular Tumors -- Chapter 21. Protein biomarkers in the management of hepatocellular carcinoma: Novel combinatory approaches -- Chapter 22. Surveillance for hepatocellular carcinoma -- Chapter 23. Use of Imaging Techniques to Screen for Hepatocellular Carcinoma -- Chapter 24. Ultrasound of Hepatocellular Carcinoma: The Important Contribution of Contrast Enhancement -- Chapter 25. MRI for Detection and Evaluation of Hepatocellular Carcinoma -- Chapter 26. Computed Tomography of HCC -- Chapter 27. Clinical features and clinician's diagnostic approach to hepatocellular carcinoma -- Chapter 28. Current HCC Staging systems: their uses and limitations -- Part C. Therapies -- Chapter 29. Percutaneous Ethanol Injection -- Chapter 30. Thermal Ablative Treatments For Hepatocellular Carcinoma -- Chapter 31. Resection of Hepatocellular Carcinoma -- Chapter 32. Liver Transplantation for Hepatocellular Carcinoma -- Chapter 33. Medical Therapy of HCC -- Chapter 34. Targeted therapies for Hepatocellular Carcinoma -- Chapter 35. Radiation Therapy for Hepatocellular Carcinoma -- Chapter 36. Psychosocial Issues in Hepatocellular carcinoma -- Chapter 37. Bringing it all together. 330 $aHepatocellular carcinoma (HCC) used to be regarded as a rare disease. However, the increasing numbers of chronic HCC carriers in the U.S. and subsequent increased incidences of HCC seen in most large medical centers means that it is no longer an uncommon disease for gastroenterologists or oncologists to encounter and its incidence and epidemiology are changing. During this exciting time in the field of HCC basic science and clinical management, many changes are simultaneously occurring at multiple levels of our understanding and management of the disease. Suddenly, there are several new choices of therapy to offer patients. Hepatocellular Carcinoma, 3rd edition addresses this fast-changing disease and gives the reader a clearer understanding of the many mechanisms involved in carcinogenesis of the liver. This comprehensive and detailed review of how to diagnose and treat hepatocellular carcinoma is written by international leaders in the field, covering both clinical treatment choices and the basic science underlying HCC development. Updated and enhanced from the last edition in 2009, Hepatocellular Carcinoma, 3rd edition features 12 new chapters including discussion of molecular markers, molecular hepatocarcinogenesis, microenvironment, heterogeneity, the new and exciting contributions of immunotherapy, and updates on the major effective hepatitis therapies that will transform HCC incidence and perhaps also the therapy. This cutting-edge text is a vital resource and must-have for today?s hepatologists and medical and surgical oncologists. "This is a well written text and should be a good reference book for those who see patients with HCC.." - Practical Gastroenterology "...a useful tool for both physicians and surgeons with a specific interest in the management of patients with HCC." - Digestive and Liver Disease. 410 0$aCurrent Clinical Oncology,$x2364-1134 606 $aOncology 606 $aHepatology 606 $aCancer$xSurgery 606 $aGastroenterology 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aHepatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33088 606 $aSurgical Oncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H59150 606 $aGastroenterology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33061 615 0$aOncology. 615 0$aHepatology. 615 0$aCancer$xSurgery. 615 0$aGastroenterology. 615 14$aOncology. 615 24$aHepatology. 615 24$aSurgical Oncology. 615 24$aGastroenterology. 676 $a610 702 $aCarr$b Brian I$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910254533503321 996 $aHepatocellular Carcinoma$91735056 997 $aUNINA